Novel drug target identified for glioblastoma treatment: breaking the never-ending feedback loop
Targeting the fibroblast growth factor 2 (FGF2) could put an end to the feedback loop involved in the pathogenesis of glioblastoma, suggests researchers from the Cleveland Clinic (OH, USA).
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>